- Home
- VEL vs ESPR Comparison
VEL vs ESPR Comparison
Compare VEL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | ESPR |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.3M | 793.7M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VEL | ESPR |
|---|---|---|
| Price | $19.77 | $3.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.75 | $6.67 |
| AVG Volume (30 Days) | 98.6K | ★ 4.0M |
| Earning Date | 05-03-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.66 | ★ 86.21 |
| EPS | ★ 1.86 | N/A |
| Revenue | N/A | ★ $332,314,000.00 |
| Revenue This Year | $5.75 | $27.49 |
| Revenue Next Year | $27.31 | N/A |
| P/E Ratio | $8.10 | ★ N/A |
| Revenue Growth | N/A | ★ 185.66 |
| 52 Week Low | $16.12 | $0.73 |
| 52 Week High | $21.40 | $4.18 |
Technical Indicators
Market Signals| Indicator | VEL | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 54.98 |
| Support Level | $19.52 | $3.16 |
| Resistance Level | $20.05 | $3.63 |
| Average True Range (ATR) | 0.52 | 0.20 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 20.20 | 78.10 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.